NIMETAZEPAM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H13N3O3
Molecular Weight	295.2927
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C3=CC=CC=C3

InChI

InChIKey=GWUSZQUVEVMBPI-UHFFFAOYSA-N

InChI=1S/C16H13N3O3/c1-18-14-8-7-12(19(21)22)9-13(14)16(17-10-15(18)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3

HIDE SMILES / InChI

Molecular Formula	C16H13N3O3
Molecular Weight	295.2927
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=35399
Curator's Comment: Description was created based on several sources, including https://www.cnb.gov.sg/drugs/bannedsubstance/nimetazepam.aspx

Nimetazepam (Erimin) is an intermediate-acting hypnotic drug which is a benzodiazepine derivative. It was first synthesized in 1962 in Japan. It does possess hypnotic, anxiolytic, sedative, and skeletal muscle relaxant properties. Nimetazepam is also an anticonvulsant. It is sold in 5 mg tablets known as Erimin. It is generally prescribed for the treatment of short-term severe insomnia in patients who have difficulty falling asleep or maintaining sleep. Nimetazepam is currently a Schedule IV drug under the international Convention on Psychotropic Substances of 1971. In Singapore, nimetazepam is a class C drug under the Misuse of Drugs Act. In Hong Kong, nimetazepam is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. Nimetazepam can only be used legally by health professionals and for university research purposes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Benzodiazepine receptors; peripheral & central 9 Target ID: CHEMBL2096683 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2857046	Binding Agent 1064		8.52 nM [Ki]
GABA-A receptor; agonist GABA site 13 Target ID: CHEMBL2109244 Sources: http://www.genome.jp/dbget-bin/www_bget?D01593	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 108 Sources: http://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=35399	Primary		Approved 8429	Erimin Approved Use This medicine helps patients with difficulty sleeping due to stress and other reasons go to sleep by acting on the central nervous system. It is usually used to treat insomnia.

PubMed

Title	Date	PubMed
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.	2009 Dec 2	19956587
Metabolic activation of benzodiazepines by CYP3A4.	2009 Feb	19005028
Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology.	2010 Aug 1	20172681
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults, take 1 tablet (5 mg of the active ingredient) at a time, before bedtime (just before going to sleep).

Route of Administration: Oral

In Vitro Use Guide

By exposure to 100 uM nimetazepam the cell viability in the presence of CYP3A4 decreased more than 25% compared with that of the control.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:28:39 GMT 2023` Edited by `admin` on `Fri Dec 15 16:28:39 GMT 2023`
Record UNII	4532264KW6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NIMETAZEPAM

Official Name

English

ERIMIN

Brand Name

English

S-1530

Code

English

NIMETAZEPAM [MART.]

Common Name

English

NIMETAZEPAM [MI]

Common Name

English

S 1530

Code

English

nimetazepam [INN]

Common Name

English

1,3-DIHYDRO-1-METHYL-7-NITRO-5-PHENYL-2H-1,4-BENZODIAZEPIN-2-ONE

Systematic Name

English

Nimetazepam [WHO-DD]

Common Name

English

NIMETAZEPAM [JAN]

Common Name

English

Classification Tree Code System Code

DEA NO.

2837